A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent
NCT03367689
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
7
Enrollment
OTHER
Sponsor class
Stopped
Very slow recruitment due to subject profile
Conditions
Breast Cancer
Interventions
DRUG:
Olaparib
Sponsor
MedSIR